ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.62 HKD | +5.65% |
|
-44.96% | -60.54% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2.297
CNY
Average target price
3.295
CNY
Spread / Average Target
+43.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.54% | 306M | |
| +48.64% | 56.65B | |
| -6.44% | 39.44B | |
| +38.59% | 39.03B | |
| +14.28% | 26.75B | |
| -11.17% | 26.86B | |
| -21.40% | 19.03B | |
| +25.64% | 12.26B | |
| +0.96% | 12.28B | |
| +27.04% | 12.04B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Presents Study Results of Cancer Drugs at European Oncology Meet
